Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The therapeutic landscape for diabetic macular edema ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including business acquisition news from Sun Pharma and Labcorp as well as new research from the National ...

Also Read: Amgen And Kyowa Kirin’s Rocatinlimab Reduces Eczema Severity In Phase 3 Study Change from baseline in the Quantitative Myasthenia Gravis (QMG) score was also greater for patients in ...

Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing therapy rocatinlimab in atopic dermatitis (AD). The 24-week IGNITE study, which ...

Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab, a T-cell rebalancing therapy, in moderate to severe atopic dermatitis.

Amgen and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announced new results from the ongoing ROCKET phase 3 clinical trial programme evaluating rocatinlimab, an investigational T-cell rebalancing therapy ...

Kyowa Kirin, Amgen’s rocatinlimab ignites positive response in Rocket study Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s ...

Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual ...